University of Groningen

Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity

Dekker, Bernadette L.; van der Horst-Schrivers, Anouk N. A.; Sluiter, Wim J.; Brouwers, Adrienne H.; Lentjes, Eef G. W. M.; Heijboer, Annemieke C.; Kobold, Anneke C. Muller; Links, Thera P.

Published in:
Thyroid

DOI:
[10.1089/thy.2018.0195](https://doi.org/10.1089/thy.2018.0195)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Dekker, B. L., van der Horst-Schrivers, A. N. A., Sluiter, W. J., Brouwers, A. H., Lentjes, E. G. W. M., Heijboer, A. C., Kobold, A. C. M., & Links, T. P. (2019). Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity. *Thyroid*, 29(1), 71-78.
<https://doi.org/10.1089/thy.2018.0195>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity

Bernadette L. Dekker,¹ Anouk N.A. van der Horst-Schrivers,¹ Wim J. Sluiter,¹ Adrienne H. Brouwers,² Eef G.W.M. Lentjes,³ Annemieke C. Heijboer,⁴ Anneke C. Muller Kobold,⁵ and Thera P. Links¹

Background: Thyroglobulin (Tg) is an established tumor marker in differentiated thyroid carcinoma (DTC). However, Tg assays can be subject to interference by autoantibodies against Tg (TgAbs). No clinical consensus exists on the cutoff value of TgAb positivity and its relationship to Tg assay interference. The aims of this study were to investigate the most applicable cutoff value for TgAb positivity in clinical practice and to evaluate whether tumor characteristics differ between TgAb+ and TgAb– patients during ablation therapy using the manufacturer's cutoff (MCO) and institutional cutoff (ICO).

Methods: This single-center cohort study included 230 DTC patients diagnosed between January 2006 and December 2014. Serum Tg and TgAbs were measured with the Tg-IRMA (Thermo Fisher Scientific) and ARCHITECT Anti-Tg (Abbott Laboratories) assays. Patients were divided into TgAb– and TgAb+ based on the limit of detection (LoD; ≥ 0.07 IU/mL), functional sensitivity (FS; ≥ 0.31 IU/mL), MCO (≥ 4.11 IU/mL), and ICO (≥ 10 IU/mL).

Results: All patients were TgAb+ based on the LoD; one patient was negative on FS. Fifty-five (23.9%) and 34 (14.8%) patients had TgAbs above the MCO and ICO, respectively. Histology, presence of multifocality, tumor-node-metastasis, and American Thyroid Association risk stratification did not differ between TgAb– and TgAb+ patients using MCO and ICO during ablation.

Conclusions: This study supports the use of a higher cutoff value than that of the FS for TgAb positivity in clinical settings. The LoD and FS are too sensitive to discriminate TgAb positivity and negativity in DTC patients during ablation therapy. The presence of TgAbs during ablation is not related to tumor characteristics and risk profile. This implies that TgAb positivity should not be considered a separate risk factor.

Keywords: thyroglobulin, thyroglobulin autoantibodies, clinical applicability, tumor characteristics, risk stratification

Introduction

THYROGLOBULIN (Tg) IS THE established tumor marker during follow-up of patients with differentiated thyroid cancer (DTC) (1–3). For Tg measurement, a highly reliable Tg assay is crucial. However, Tg assays can be subject to interference by Tg antibodies (TgAbs), which can result in false-negative (e.g., undetectable) or false-positive Tg values, depending on the assay (4–7). In 18–29% of DTC pa-

tients, TgAb values are detectable, the number depending on the cutoff value that is used (8–11). Because no Tg immunoassay is completely free from interferences, TgAb analysis should be performed parallel to each Tg measurement (4,5). Until now, there is no clinical consensus on the definition of TgAb positivity and its relation to Tg assay interference. The literature proposes several cutoff values for TgAb positivity. The first is the limit of detection (LoD), based on the argument that even very low TgAb values can interfere with the

Departments of ¹Endocrinology and ²Nuclear Medicine and Molecular Imaging; ³Laboratory Medicine; University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

⁴Department of Clinical Chemistry and Hematology, Laboratory of Endocrinology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

⁵Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, VU University, Amsterdam, The Netherlands.

Tg assay (12,13). Second, the limit of quantification (LoQ) has been recommended, since this provides more certainty about the validity of the measured TgAb concentration and the possibility of a potential relevant interference in the patient (5). Some prefer to use functional sensitivity (FS) instead of the LoQ because it is determined over a long clinical time span (6–12 months) (14,15). A third possibility for a cutoff value is the use of the manufacturer's cutoff (MCO). However, as the MCO has often been determined for use in diagnosing patients with thyroid autoimmunity, it is therefore considered to be unsuitable for detecting TgAb interference (5,13). Finally, every reagent manufacturer states in its package insert instructions that each laboratory should establish its own specific TgAb assay reference value for its own patient population (institutional cutoff [ICO]). These different approaches, leading to varying TgAb cutoff values, have contributed to uncertainty regarding the definition of TgAb positivity and consequently to uncertainty regarding the disease status of DTC patients with measured TgAbs (4,5,16). In addition to the discussion about the cutoff value of TgAbs, there is growing evidence for the value of trends in serum TgAb levels and disease activity (9,17,18).

The presence of TgAbs during initial treatment has unequivocal consequences for initial risk stratification and follow-up strategies, depending on the guidelines used. The European Thyroid Association recommends periodic neck ultrasound and ^{131}I scans to monitor TgAb+ Tg undetectable patients (19). The Dutch DTC guideline considers patients with detectable TgAb before/during ablation therapy as intermediate/high risk, as Tg cannot be considered a reliable tumor marker (20). The American Thyroid Association (ATA) and the British Thyroid Association DTC guidelines do not include the presence of TgAbs in their initial risk stratification, but rather they emphasize the value of trends in the TgAb levels in relation to disease activity (21,22). Likewise, the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) system, used to predict mortality, does not take into account TgAb, but merely focuses on tumor size and lymph node and distant metastases (23).

Therefore, the first aims of this study were to investigate which cutoff value for TgAb positivity is the most applicable for clinical practice, and to evaluate whether tumor characteristics differ between TgAb+ and TgAb– patients during ablation therapy, using different cutoff values. The next aim was to evaluate the value of TgAbs as a risk factor in a low-risk patient group according to the Dutch DTC guidelines.

Methods

Study design and population

In this single-center cohort study, all consecutive patients who were diagnosed with DTC between January 1, 2006, and December 31, 2014, and who received their treatment and/or follow-up at the University Medical Center Groningen (UMCG) were identified from the DTC database in which patients are included prospectively. Patients were treated according to the Dutch DTC guidelines (20). In general, the initial procedure consisted of a (near) total thyroidectomy with or without additional lymph node dissection. After surgery, the patients received ^{131}I ablation therapy after thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH) upon clinical indication.

Data collection

The patients' medical data were obtained through the database and from their electronic medical records using the hospital information system. According to the Dutch Medical Research Involving Human Subjects Act, no separate approval was needed. Analyses were performed on fully anonymized data sets.

Study definitions

DTC was defined as papillary and follicular thyroid carcinoma (including all subtypes). The date of diagnosis was defined as the date of histological confirmation of DTC. Histological diagnosis, TNM classification, and thyroiditis were confirmed by the pathology department of the UMCG. The original histology of all patients referred to the thyroid cancer center after being operated in another hospital were revised by two experienced pathologists.

Tumors were staged and reclassified according to the seventh edition of the AJCC/UICC TNM system for DTC (23). Hashimoto's thyroiditis (HT) was defined as the presence of a diffuse lymphocytic infiltration in the thyroid gland combined with (i) germinal center formation, (ii) thyroid follicle obliteration, and (iii) epithelium destruction. In some pathological reports, a diffuse lymphocytic infiltration was only mentioned with one or two additional characteristics; these cases were also defined as HT. All the other descriptions of thyroiditis were not considered to be HT. The duration of follow-up was calculated in years from the date of diagnosis until March 1, 2016.

The initial Tg and TgAb levels were determined during THW or after rhTSH stimulation, shortly before the ^{131}I ablation therapy.

To monitor TgAb trends and disease state, the change of TgAbs during follow-up was compared to the disease state after the change. Changes in TgAbs (based on the ICO) were defined as no TgAbs present, TgAbs switch negative to positive, TgAbs switch positive to negative, TgAbs increase $\geq 50\%$ of a positive value, stable positive value ($< 50\%$ change), and TgAbs decrease $\geq 50\%$ of a positive value.

Disease state was classified as in remission, persistent, or recurrent disease. Remission was defined as absence of clinical, scintigraphic, and/or radiological evidence of disease and Tg $< 1.0 \text{ ng/mL}$ during TSH suppressive therapy for at least one year after the initial ^{131}I therapy. Persistent disease was defined as presence of disease, radiologically and/or biochemically proven (Tg $\geq 1.0 \text{ ng/mL}$ under TSH suppressive therapy) within one year after the initial ^{131}I therapy. Recurrent disease was defined as presence of disease, radiologically and/or biochemically proven (Tg $\geq 1.0 \text{ ng/mL}$ under TSH suppressive therapy), after remission following the initial ^{131}I therapy.

The cumulative administrative ^{131}I dose was calculated using the administered ablation and subsequent therapeutic dosages.

Laboratory measurements and definitions

The lower LoD of the assay is defined as the value corresponding to a signal 2 standard deviations (SD) above the mean of 10 replicates of the zero calibrator. FS is the level of the analyte at which the assay is able to reproduce the results with an interassay coefficient of variation of 20% over a 6- to 12-month time span. The Tg immunoradiometric assay (Tg-IRMA) by Thermo Fisher Scientific (Henningsdorf,

Germany) was used for the detection of Tg. This assay is calibrated indirectly against the Certified Reference Material (CRM) 457 standard by using an adjustment factor. However, since there is some discussion concerning the exact value of the adjustment factor as stated in the kit insert, this study used the uncorrected results of the Tg assay (24). The Tg-IRMA has a LoD of 0.1 ng/mL and FS of 0.3 ng/mL. Tg-IRMA levels <0.1 ng/mL were defined as analytically undetectable. TgAbs were determined with a chemoluminescence immunoassay (ARCHITECT Anti-Tg assay; Abbott Laboratories, Chicago, IL). This assay is calibrated against the World Health Organization 1st International Reference Preparation (IRP) 65/093. The LoD and FS of this assay are 0.07 IU/mL and 0.31 IU/mL, respectively, and the MCO is 4.11 IU/mL. The ICO of this assay is ≥ 10 IU/mL, determined by the authors' own laboratory by remeasuring sera of 120 controls free of thyroid disease. Subject selection of these controls was performed according to guideline 33 of the National Academy of Clinical Biochemistry guidelines, with the adaptation that the controls consisted of both men and women (25). Between 2006 and 2014, two TgAb assays were used: the ARCHITECT Anti-Tg assay and the Brahms anti-Tg assay (Thermo Fisher Scientific). However, the use of the anti-Tg assay from Brahms turned out to have no added value, which resulted, since 2014, in the use of only the ARCHITECT Anti-Tg assay (unpublished data).

Risk stratification

The study population was classified according to the seventh edition of the AJCC/UICC TNM system (23), the initial ATA classification (2015) (21), and the Dutch DTC risk stratification (2014) (20). In short, according to the Dutch DTC risk stratification, low-risk patients were defined as those with a T1 or T2 minimal invasive follicular, or a classic papillary carcinoma with N0 or N1a (level VI) lymph node involvement without extranodal extension, detectable Tg with negative TgAbs shortly before surgery or during ablation therapy, and no radioiodine uptake outside the thyroid bed on the post-ablation scan. Patients not meeting low-risk criteria were classified as intermediate or high risk (20).

Study method

For the first aim, the study population was divided into TgAb- and TgAb+ patients based on cutoff levels according to LoD (≥ 0.07 IU/mL), FS (≥ 0.31 IU/mL), MCO (≥ 4.11 IU/mL), and ICO (≥ 10 IU/mL). Furthermore, each patient was classified according to the AJCC/UICC TNM system and the initial ATA and Dutch DTC risk-stratification criteria. Following the first aim, the study evaluated whether tumor characteristics differed between TgAb+ and TgAb- patients during ablation therapy using the different cutoff levels mentioned above. The second aim of the study was to evaluate the patients with low-risk histopathological tumor characteristics according to the Dutch guidelines, and to subclassify them as TgAb+ or TgAb-.

Statistical analysis

Normally distributed data are expressed as the mean $\pm$ SD, and nonparametric distributed data as the median with interquartile range (IQR). For comparison of normally distributed

data, Student's *t*-test was performed. Nonparametric continuous data were compared using the Mann-Whitney *U*-test. Categorical data were compared using Pearson's chi-square test or Fisher's exact test. *p*-Values <0.05 were considered significant. IBM SPSS Statistics for Windows v22.0 (IBM Corp., Armonk, NY) was used for statistical analysis of the data.

Results

General patient characteristics

The study population consisted of 230 patients. Of these, 155 (67%) were female, and 180 (78%) were diagnosed with papillary thyroid carcinoma (PTC). The mean age at diagnosis was 48 ± 18 years, and the median follow-up was 6 years (IQR 2–8 years). The characteristics of the study population are summarized in Table 1.

Patient characteristics according to different TgAb cutoff levels during ablation therapy

Applying the LoD (0.07 IU/mL) as the cutoff value for TgAb positivity, all 230 patients would be classified as TgAb+. Therefore, no comparison could be made for tumor characteristics using this cutoff value. The same was true for FS (0.31 IU/mL), as 229 patients would be considered to be TgAb+. One female patient had a TgAb value <0.31 IU/mL during ablation therapy. She was diagnosed with a T2N1aM0 PTC at 37 years of age, and during follow-up she was clinically in remission with stable TgAb levels around 0.5 IU/mL. Out of 230 patients, 55 (23.9%) had TgAbs above the MCO of 4.11 IU/mL, and 34 (14.8%) had a TgAb value above the cutoff value of 10 IU/mL. Table 1 shows the clinical characteristics of TgAb- and TgAb+ patients using the MCO and ICO. There were no differences in sex, age at diagnosis, presence of multifocality, TNM, ATA risk stratification, or disease state after initial treatment. The median cumulative administrative ^{131}I dose was significantly higher in the TgAb+ group compared to the TgAb- group when using both the MCO (11.1 GBq [11.1–16.7 GBq] and 11.1 GBq [5.6–11.1 GBq]; $p=0.001$) and the ICO (11.1 GBq [11.1–15.3 GBq] and 11.1 GBq [5.6–11.1 GBq]; $p=0.003$). Using the MCO and ICO as the cutoff value, HT was significantly more present in TgAb+ patients compared to TgAb- patients: 26 (47.3%) and 10 (5.7%), respectively, using the MCO ($p<0.001$) and 18 (52.9%) and 18 (9.2%), respectively, using the ICO cutoff ($p<0.001$). The median Tg value of the TgAb+ patients was significantly lower compared to the Tg value in the TgAb- group (MCO: 1.0 ng/mL [0.1–5.7 ng/mL] and 3.7 ng/mL [1.3–16.0 ng/mL], $p<0.001$; ICO: 0.5 ng/mL [0.1–2.9 ng/mL] and 3.7 ng/mL [1.2–16.0 ng/mL], $p<0.001$). The percentage of patients with undetectable Tg was significant higher in the TgAb+ group compared to the percentage in the TgAb- group (MCO: 25.5% and 9.7%, $p<0.003$; ICO: 38.2% and 9.2%, $p<0.001$).

Trends in TgAbs and disease activity

Persistent/recurrent disease was observed in five out of six patients after the TgAb conversion from negative to positive and in two out of three patients with an increase of $\geq 50\%$ of a positive value. Remission was observed in six out of six patients after the TgAb conversion from positive to negative, and in 21/24 patients with a decrease of $\geq 50\%$ of a positive TgAb value (Table 2; $p=0.008$).

TABLE 1. CHARACTERISTICS OF TgAb- AND TgAb+ PATIENTS (TgAbs+ ≥ 4.11 IU/mL AND ≥ 10 IU/mL)

	Total	MCO		ICO	
		TgAbs <4.11	TgAbs ≥ 4.11	TgAbs <10.0	TgAbs ≥ 10.0
<i>n</i>	230	175	55	196	34
Sex (male/female)	75/155	62/113	13/42	67/129	8/26
Age at diagnosis, years	49.0 (34.0–62.0)	49.0 (34.0–61.0)	48.0 (29.0–62.0)	49.0 (34.0–61.0)	52.5 (28.5–68.0)
Follow-up, years	6.0 (2.0–8.0)	6.0 (2.0–8.0)	6.0 (3.0–8.0)	6.0 (2.0–8.0)	6.0 (3.0–8.0)
Histology					
Papillary	180 (78.3)	135 (77.1)	45 (81.8)	153 (78.1)	27 (79.4)
Follicular	50 (21.7)	40 (22.9)	10 (18.2)	43 (21.9)	7 (20.6)
Thyroiditis	36 (15.7)	10 (5.7)	26 (47.3) ^a	18 (9.2)	18 (52.9) ^a
Multifocality	116 (50.4)	86 (49.1)	30 (54.5)	97 (49.5)	19 (55.9)
TNM classification					
T1–T2	117 (50.9)	90 (51.4)	27 (49.1)	100 (51.0)	17 (50.0)
T3–T4	113 (49.1)	85 (48.6)	28 (50.9)	96 (49.0)	17 (50.0)
N0	131 (57.0)	101 (57.7)	30 (54.5)	114 (58.2)	17 (50.0)
N1	99 (43.0)	74 (42.3)	25 (45.5)	82 (41.8)	17 (50.0)
M0	213 (92.6)	162 (92.6)	51 (92.7)	180 (91.8)	33 (97.1)
M1	17 (7.4)	13 (7.4)	4 (7.3)	16 (8.2)	1 (2.9)
AJCC stage grouping					
Stage 1	103 (44.8)	80 (45.7)	23 (41.8)	91 (46.4)	12 (35.3)
Stage 2	26 (11.3)	17 (9.7)	9 (16.4)	18 (9.2)	8 (23.5)
Stage 3	49 (21.3)	41 (23.4)	8 (14.5)	43 (21.9)	6 (17.6)
Stage 4A	35 (15.2)	23 (13.1)	12 (21.8)	28 (14.3)	7 (20.6)
Stage 4B	3 (1.3)	3 (1.7)	—	3 (1.5)	—
Stage 4C	14 (6.1)	11 (6.3)	3 (5.5)	13 (6.6)	1 (2.9)
ATA risk stratification					
Low risk	76 (33.0)	54 (30.9)	22 (40.0)	62 (31.6)	14 (41.2)
Intermediate risk	89 (38.7)	76 (43.4)	13 (23.6)	81 (41.3)	8 (23.5)
High risk	65 (28.3)	45 (25.7)	20 (36.4)	53 (27.0)	12 (35.3)
Dutch risk stratification					
Low risk	38 (16.5)	33 (18.9)	5 (9.1)	38 (19.4)	—
High risk	192 (83.5)	142 (81.1)	50 (90.9)	158 (80.6)	34 (100.0)
Cumulative ¹³¹ I dose (GBq)	11.1 (5.6–11.1)	11.1 (5.6–11.1)	11.1 (11.1–16.7) ^a	11.1 (5.6–11.1)	11.1 (11.1–15.3) ^b
Disease state					
Remission	179 (77.8)	137 (78.3)	42 (76.4)	151 (77.0)	28 (82.4)
Persistent disease					
Biochemical	14 (6.1)	10 (5.7)	4 (7.3)	12 (6.1)	2 (5.9)
Structural	4 (1.7)	2 (1.1)	2 (3.6)	2 (1.0)	2 (5.9)
Both	32 (13.9)	26 (14.9)	6 (10.9)	31 (15.8)	1 (2.9)
Recurrent disease					
Biochemical	—	—	—	—	—
Structural	—	—	—	—	—
Both	1 (0.4)	—	1 (1.8)	—	1 (2.9)
Tg, ng/mL	3.0 (0.7–14.0)	3.7 (1.3–16.0)	1.0 (0.1–5.7) ^a	3.7 (1.2–16.0)	0.5 (0.1–2.9) ^a
N undetectable Tg	31 (13.5)	16 (9.1)	14 (25.5) ^b	17 (8.7)	13 (38.2) ^a
TgAbs, IU/mL	1.4 (0.8–3.7)	1.0 (0.7–1.9)	19.4 (7.5–57.9) ^a	1.1 (0.7–2.3)	47.7 (24.8–143.3) ^a

Data shown are median (IQR) or *n* (%). Serum Tg and TgAbs measured during THW shortly before ¹³¹I ablation therapy; TgAb levels ≥ 4.11 IU/mL (MCO) and ≥ 10.0 IU/mL (ICO) were considered positive.

^a*p* < 0.001, TgAbs <4.11 vs. ≥ 4.11 IU/mL and TgAbs <10.0 vs. ≥ 10 IU/mL.

^b*p* = 0.003, TgAbs <4.11 vs. ≥ 4.11 IU/mL and TgAbs <10.0 vs. ≥ 10 IU/mL.

TgAb, thyroglobulin autoantibodies; MCO, manufacturer's cutoff; ICO, institutional cutoff; TNM, tumor-node-metastasis; AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; IQR, interquartile range; THW, thyroid hormone withdrawal.

Dutch DTC risk stratification

Out of the cohort of 230 patients, 192 were classified as high risk according to the Dutch risk-stratification criteria. Focusing on these 192 patients, 186 were classified as high risk based on tumor characteristics with or without a TgAb

values above the ICO of 10 IU/mL. The remaining six patients were classified as high risk, not due to tumor characteristics but due to TgAb levels above the ICO of 10 IU/mL. Thirty-eight patients were classified as low risk based on their tumor characteristics and the TgAb values. Table 3 shows the characteristics, treatment, and outcomes of the 44 patients

TABLE 2. TRENDS IN TgABS BASED ON THE ICO AND DISEASE ACTIVITY

		Disease state after change in TgAbs (ICO)	
		Remission	Persistent/recurrent disease
Change in TgAbs (ICO, N=230)	N=39 (191) ^a	29	10
Negative → positive*	6	1 (16.6%)	5 (83.3%)
Positive → increase ≥50%*	3	1 (33.3%)	2 (66.7%)
Positive → negative*	6	6 (100%)	—
Positive → decrease ≥50%*	24	21 (87.5%)	3 (12.5%)

^a191 patients were TgAb– upon diagnosis and did not become positive during follow-up.

**p*=0.008.

classified as low risk solely based on tumor characteristics. During follow-up, all six patients with initial TgAb positivity were in remission with declining TgAb levels (Fig. 1). Of the remaining 38 low-risk patients, 89.5% were in remission one year after initial therapy; four patients showed persistent disease.

Discussion

This study demonstrates that as cutoff levels to define TgAb positivity in DTC patients during ablation therapy, the LoD and FS are not useful in clinical practice because they render Tg useless as a tumor marker, since almost all patients had TgAbs above these cutoff values. Using the MCO or ICO as a cutoff value for these patients is more reasonable in clinical practice. In this study, based on the MCO or ICO, the TgAb+ patients showed no differences in tumor character-

istics and risk profiles compared to the TgAb– patients. This implies that TgAb positivity should not be considered a separate risk factor.

Latrofa *et al.* illustrated that low levels of TgAb can interfere with the Tg assay but that metastatic disease can be ruled out when TgAb levels are below the MCO and Tg is not detectable (26). They nicely illustrated the difference between analytical and clinical relevance regarding the interference of low TgAbs with the Tg assay. The study by Côrtes *et al.* demonstrated that low- or intermediate-risk patients with borderline TgAbs (TgAb values between FS and MCO), undetectable Tg, and normal ultrasound after initial treatment are not at a greater risk for tumor persistence or recurrence compared to patients with undetectable TgAbs (27). The present study shows that using the MCO or ICO, TgAb+ patients have significantly lower Tg values. This may, however, reflect an analytical interference that may not be of

TABLE 3. DIFFERENCES IN CHARACTERISTICS OF LOW-RISK PATIENTS CLASSIFIED ACCORDING TO TUMOR CHARACTERISTICS AND TgAB VALUE

	Total	MCO		ICO	
		TgAbs <4.11	TgAbs ≥4.11	TgAbs <10	TgAbs ≥10
<i>n</i>	44	33	11	38	6
Sex, male/female	7/37	7/26	0/11	7/31	0/6
Follow-up, years	4.0 (2.0–8.0)	4.0 (2.0–8.0)	4.0 (1.0–8.0)	4.00 (2.0–8.0)	6.0 (2.5–9.0)
Thyroiditis	12 (27.3)	4 (12.1)	8 (72.7)	7 (18.4)	5 (83.3)
ATA risk stratification					
Low risk	38 (86.4)	27 (81.1)	11 (100.0)	32 (84.2)	6 (100.0)
Intermediate risk	6 (13.6)	6 (18.2)	—	6 (15.8)	—
High risk	—	—	—	—	—
Cumulative ¹³¹ I dose, GBq	6.5 (5.6–11.1)	5.5 (5.5–11.1)	11.1 (5.5–16.7)	5.6 (5.6–11.1)	13.9 (9.3–16.7)
Disease state					
Remission	40 (90.9)	30 (90.9)	10 (90.9)	34 (89.5)	6 (100)
Persistent disease					
Biochemical	1 (2.3)	—	1 (9.1)	1 (2.6)	—
Structural	—	—	—	—	—
Both	3 (6.8)	3 (9.1)	—	3 (7.9)	—
Recurrent disease					
Biochemical	—	—	—	—	—
Structural	—	—	—	—	—
Both	—	—	—	—	—
Tg, ng/mL	2.2 (0.9–9.4)	2.4 (0.9–9.1)	2.0 (0.42–13.0)	2.1 (0.9–8.8)	3.7 (0.4–70.8)
TgAbs, IU/mL	2.0 (0.7–4.7)	1.0 (0.7–2.7)	12.9 (6.5–26.5)	1.2 (0.7–3.2)	25.7 (17.8–71.4)

Data shown are median (IQR) or *n* (%). Serum Tg and TgAbs measured during THW shortly before ¹³¹I ablation therapy; patients with TgAb levels ≥10 IU/mL were considered intermediate/high risk. TgAb trends based on initial TgAb value and TgAb value after two years of diagnosis.

FIG. 1. Changes in thyroglobulin autoantibody (TgAb) levels during follow-up of six patients classified as intermediate/high risk based on TgAbs.

relevance in clinical decision making, as suggested by La-trofa *et al.* and Côrtes *et al.* (26,27).

Furthermore, as suggested in the recent literature, with the increasing availability and development of high-sensitive Tg assays and Tg quantification with liquid chromatography tandem mass spectrometry, Tg may be more reliably monitored even in the presence of TgAbs (28,29).

Related to this subject is the clinically relevant issue of whether TgAb positivity, using the MCO or ICO, led to a negative Tg measurement in the presence of structural disease. In the patient data, it was not found that the presence of TgAbs, based on the MCO and ICO, prevents or delays the detection of persistent or recurrent disease (data available on request). The TgAb+ patients with a concomitant Tg <1.0 ng/mL showed no structural disease, defined as lymph node or distant metastases revealed by ultrasound and ^{131}I whole-body scans.

The relevance of detectable TgAbs during ablation therapy and their effect on the risk status of DTC patients has been a point of controversy in some guidelines and earlier studies (9–11,30–33). The present study demonstrates that patients with TgAbs during ablation therapy do not differ with regard to tumor characteristics and risk profile, and the data do not support their use as a separate risk factor. These findings are not in line with the study by Durante *et al.* in which 220 TgAb+ PTC patients were compared to a control group of 1020 TgAb– PTC patients. They concluded that TgAb+ patients differed concerning tumor characteristics and long-term clinical outcomes. At baseline, TgAb+ patients more often had extrathyroidal extension and were

more frequently classified as high risk according to the ATA risk classification (32). However, this was a multicenter study with a heterogeneous patient population in which TgAb positivity was established after a range of 1–12 months after initial treatment, that is, (near)total thyroidectomy plus cervical lymph node dissection and/or radioiodine ablation. Furthermore, TgAb positivity was defined without specific details as to the assays and cutoff values used. Trimboli *et al.* found that positive TgAbs prior to ^{131}I ablation therapy indicated a higher risk of poor prognosis (33). This is in contrast to the disease outcome in the present study, in which TgAb+ patients received more ^{131}I as a result of national guidelines. This could possibly explain the equal disease outcomes in the TgAb+ and TgAb– patients. For this reason, conclusions regarding disease outcome could not be made in this study group.

As expected, HT was significantly more frequent in TgAb+ patients. Other studies also report a higher prevalence of HT in TgAb+ patients, which probably reflects the autoimmune process associated with HT (9,17). The prevalence of HT in DTC varies from 0.5% to 30%, depending, among other factors, on the population studied and the definition of HT (13,30,34–39). The causal pathway between HT and DTC and the prognostic value of the presence of lymphocytic thyroiditis remain elusive (13).

Several DTC guidelines and original articles emphasize the use of TgAb levels as surrogate tumor markers. TgAbs appear to change in response to changes in the mass of Tg-secreting tissue, trends that could help to provide more certainty regarding the disease status (6,13,19–22,40). Therefore, Tg and

TgAbs always have to be measured concomitantly in all patients, and clinical decision making depends on the levels of these markers. Despite limited numbers, the results support the statement that TgAb trends are, over time, markers of disease activity. When comparing the change in TgAbs during follow-up with the disease state after the change, it was found that patients with an increase of TgAb were found to have persistent/recurrent disease and patients with decreasing TgAb values were in remission.

The six patients classified as high risk according to the national guidelines, with TgAb levels above the ICO but with low-risk tumor characteristics, showed all declining values during the two years of follow-up. These results also suggest that in low-risk patients with TgAbs, decreasing TgAb trends can be used to support less aggressive treatment.

This study has strengths and limitations. The data were taken from a homogenous patient group from a single institution using one Tg and TgAb assay during a long period of follow-up. Differences between TgAb assays are generally known. However, the main message of our study is the importance of the definition of TgAb positivity (i.e., the cutoff value of the TgAb assay), which is independent of the assay used.

In conclusion, the present data support the use of MCO or ICO cutoff values instead of the LoD or FS for TgAb positivity in the clinical setting. However, in accordance with the manufacturer, the use of the regional ICO for TgAb positivity is preferable to the MCO. Furthermore, TgAb positivity itself cannot be considered a separate risk factor and should presumably not be considered an independent risk factor for risk stratification.

Author Disclosure Statement

All of the authors can assure that the manuscript represents honest work and that no actual or potential financial interest is capable of influencing judgment.

References

1. Evans C, Tennant S, Perros P 2016 Serum thyroglobulin in the monitoring of differentiated thyroid cancer. *Scand J Clin Lab Invest Suppl* **245**:119–123.
2. Francis Z, Schlumberger M 2008 Serum thyroglobulin determination in thyroid cancer patients. *Best Pract Res Clin Endocrinol Metab* **22**:1039–1046.
3. Phan HTT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JTM, Dierckx RA, Wolffenbuttel BH, Links TP 2008 The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. *Eur J Endocrinol* **158**:77–83.
4. Hoofnagle AN, Roth MY 2013 Improving the measurement of serum thyroglobulin with mass spectrometry. *J Clin Endocrinol Metab* **98**:1343–1352.
5. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Rimmel H, Seregni E, Smit JWA, Theimer C, Giovanella L 2013 Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. *Thyroid* **23**:1211–1225.
6. Spencer C, Fatemi S 2013 Thyroglobulin antibody (TgAb) methods—strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. *Best Pract Res Clin Endocrinol Metab* **27**:701–712.

7. Netzel BC, Grebe SKG, Carranza Leon BG, Castro MR, Clark PM, Hoofnagle AN, Spencer CA, Turcu AF, Algeciras-Schimmich A 2015 Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. *J Clin Endocrinol Metab* **100**:1074–1083.
8. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **83**:1121–1127.
9. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY 2002 Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. *Clin Endocrinol (Oxf)* **57**:215–221.
10. Görges R, Maniecki M, Jentzen W, n-Yi Sheu S, Mann K, Bockisch A, Janssen OE 2005 Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. *Eur J Endocrinol* **153**:49–55.
11. Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM 1994 Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. *Thyroid* **4**:199–202.
12. Spencer C, Petrovic I, Fatemi S 2011 Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. *J Clin Endocrinol Metab* **96**:1283–1291.
13. Spencer CA 2011 Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). *J Clin Endocrinol Metab* **96**:3615–3627.
14. Spencer C 2013 Commentary on: implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. *Thyroid* **23**:1190–1192.
15. Spencer C, Petrovic I, Fatemi S, LoPresti J 2014 Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. *J Clin Endocrinol Metab* **99**:4589–4599.
16. Spencer CA, LoPresti J, Fatemi S 2014 How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. *Curr Opin Endocrinol Diabetes Obes* **21**:394–404.
17. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu J, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **93**:4683–4689.
18. Seo JH, Lee SW, Ahn B, Lee J 2010 Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using ¹⁸F-FDG PET/CT. *Clin Endocrinol (Oxf)* **72**:558–563.
19. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W and the European Thyroid Cancer Taskforce

- 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* **154**:787–803.
20. Comprehensive Cancer Centre the Netherlands. Oncoline, cancer clinical practice guidelines. Available at: www.oncoline.nl/schildklier carcinoom (accessed October 2, 2017).
 21. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L 2016 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **26**:1–133.
 22. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerard BAG, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR 2014 Guidelines for the management of thyroid cancer. *Clin Endocrinol (Oxf)* **81**:1–122.
 23. Sobin LH, Gospodarowicz MK, Wittekind Ch (eds) 2009 International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. Seventh edition. Wiley-Blackwell, Oxford.
 24. Groen AH, Klein Hesselink MS, Plukker JTM, Sluiter WJ, van der Horst-Schrivers ANA, Brouwers AH, Lentjes EGWM, Muller Kobold AC, Links TP 2016 Additional value of a high sensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* **86**:1–6.
 25. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR; Guidelines Committee, National Academy of Clinical Biochemistry 2003 Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid* **13**:3–126.
 26. Latrofa F, Ricci D, Sisti E, Piaggi P, Nencetti C, Marino M, Vitti P 2016 Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma. *Thyroid* **26**:798–806.
 27. Côrtes MCS, Rosario PW, Oliveira LFF, Calsolari MR 2018 Clinical impact of detectable antithyroglobulin antibodies below the reference limit (bordeline) in patients with papillary thyroid carcinoma with undetectable serum thyroglobulin and normal neck ultrasonography after ablation: a prospective study. *Thyroid* **28**:229–235.
 28. Giovanella L, Imperiali M, Verburg FA, Trimboli P 2018 Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high sensitive Tg assays. *Eur J Endocrinol* **178**:75–82.
 29. Trimboli P, Imperiali M, Piccardo A, Campenni A, Giordani I, Ruggeri RM, Baldari S, Orlandi F, Giovanella L 2018 Multicentre clinical evaluation of the new highly sensitive Elecsys thyroglobulin II assay in patients with differentiated thyroid carcinoma. *Clin Endocrinol* **88**:295–302.
 30. Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A 2010 Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto's thyroiditis. *Eur Surg Res* **45**:333–337.
 31. Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B 1990 Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. *J Endocrinol Invest* **13**:737–742.
 32. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F 2014 Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. *Thyroid* **24**:1139–1145.
 33. Trimboli P, Zilioli V, Imperiali M, Giovanella L 2017 Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. *Clin Chem Lab Med* **55**:1995–2001.
 34. Feldt-Rasmussen U, Rasmussen AK 2010 Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. *Hormones* **9**:109–117.
 35. Schäffler A, Palitzsch KD, Seiffarth C, Höhne HM, Riedhammer FJ, Hofstädter F, Schölmerich J, Rüschhoff J 1998 Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. *Eur J Clin Invest* **28**:838–844.
 36. Loh K, Greenspan FS, Dong F, Miller TR, Yeo PPB 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* **84**:458–463.
 37. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP 1999 Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management and outcome. *Surgery* **126**:1070–1077.
 38. Kebebew E, Treseler PA, Ituarte PHG, Clark OH 2001 Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. *World J Surg* **25**:632–637.
 39. Lee J, Kim Y, Choi JW, Kim Y 2013 The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. *Eur J Endocrinol* **168**:343–349.
 40. Matrone A, Latrofa F, Torregrossa L, Piaggi P, Gambale C, Faranda A, Ricci D, Agate L, Molinaro E, Basolo F, Vitti P, Elisei R 2018 Changing trend of thyroglobulin antibodies patients with differentiated thyroid cancer without ¹³¹I ablation. *Thyroid* **28**:871–879.

Address correspondence to:

Thera P. Links, MD, PhD
Department of Endocrinology, HPC AA31
University Medical Center Groningen
University of Groningen
P.O. Box 30.001
9700 RB Groningen
The Netherlands

E-mail: t.p.links@umcg.nl

This article has been cited by:

1. Bastiaan Sol, Bert Bravenboer, Brigitte Velkeniers, Steven Raeymaeckers, Marleen Keyaerts, Corina Emilia Andreescu. 2021. Undetectable thyroglobulin makes 123I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study. *Thyroid Research* **14**:1. . [[Crossref](#)]
2. Fátima Ramos da Silva, Pedro W. Rosario, Gabriela F. Mourão. 2021. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies. *Clinical Endocrinology* **18**. . [[Crossref](#)]
3. J.J. Hillebrand, S.E. Siegelaa, A.C. Heijboer. 2020. Falsely decreased thyroglobulin levels in a patient with differentiated thyroid carcinoma. *Clinica Chimica Acta* **509**, 217-219. [[Crossref](#)]